Abstract
The present disclosure, in part, relates to novel, relates to novel, prognostic tools for severe COVID-19 disease, including identification of a set of clinical parameters that can be used to generate a clinical risk score of COVID-19 complications. The present disclosure also relates to proteomic panel-profiling of patients with severe COVID-19 complications versus mild-moderate symptoms to characterize biological processes and pathways associated with disease severity. Also disclosed are identified molecular changes associated with the clinical findings that can be used to generate a molecular severity score. In addition, the methods disclosed here relate to identifying effective methods of treatments based on the patient analysis.
| Original language | English |
|---|---|
| Patent number | US2024094217 |
| IPC | G01N 33/ 68 A I |
| Priority date | 25/11/21 |
| Publication status | Published - 21 Mar 2024 |